Modern phage therapy: 2024–2025 clinical advances and opportunities in Georgia

Key clinical results (2024–2025)

Phage therapy represents a safe, validated, and promising alternative against multidrug-resistant infections.
— Journal of Clinical Investigation, 2025

“Integrating phage therapy into modern hospital protocols is no longer a question of ‘if’, but of ‘when’.”
— Nature Microbiology, 2024

For several decades, the rise of multidrug-resistant bacteria has made conventional antibiotic treatments increasingly ineffective. In response to this crisis, phage therapy is returning to the forefront as a targeted, non-toxic, and adaptable option. Reviews such as those in Nature Microbiology emphasize that integrating phages into modern protocols is a matter of “when” rather than “if”. For example, the article Advocating for phage therapy reports that, across 43 phage lots used clinically, a clinical improvement was observed in 77.2% of cases.

Study by Uchechukwu & Shonekan (Journal of Medical Microbiology)

The article “Current status of clinical trials for phage therapy” analyzes more than 40 clinical trials worldwide (skin, urinary, pulmonary, and bone infections).
The authors emphasize three essential criteria for effectiveness:

the need for an in vitro test proving that the bacterial strain is sensitive to the phage
a sufficient concentration (high titer),
and the optimal choice of the administration route.

Among the notable results:

in chronic Pseudomonas otitis, a phage cocktail led to significant clinical improvement and a reduction in bacterial load;
in chronic rhinitis caused by Staphylococcus aureus, administering three phages over 7 to 14 days led to complete eradication in some cases and a clear reduction in bacterial growth in the others.
Overall tolerability is excellent: no serious adverse effects have been reported, even in trials combining antibiotics and phages.

Data on pulmonary infections (Sarkodie-Addo et al.)

A review in the Journal of Respiratory Medicine compiled human data on phages in respiratory infections.
The most encouraging results involve patients with cystic fibrosis infected with Pseudomonas aeruginosa: phage nebulization reduced microbial load and improved clinical parameters without major side effects.
Conditions for success include a strong phage–bacteria match, stable formulations, and an appropriate dosage regimen.
However, trials remain limited and often observational, which restricts the statistical strength of the conclusions.

Recent cases of personalized nebulized therapies

A study published in Nature Medicine (Chan et al., 2025) reports an experience involving nine adults with cystic fibrosis: personalized nebulized therapy led to a median decrease of 10⁴ CFU/mL in Pseudomonas levels in sputum, without altering the lung microbiome. Patients also showed an improvement in FEV₁ of 6 to 8%.
Another European observational study (100 cases) found clinical improvement in 77.2% of cases and bacterial eradication in 61.3%, often in combination with antibiotics.

Summary of phage treatment outcomes (2018–2023)

Clinical data collected over the 2018–2023 period confirm the trends observed recently: phage therapy shows real effectiveness, excellent tolerability, and particular usefulness in resistant or chronic infections.
A systematic review covering 1,904 patients treated with phages reports that around 79% showed a significant clinical improvement and, in more than half of cases, complete eradication of the targeted bacterium.

Osteoarticular and prosthetic infections are among the most well-documented: patients with recurrent infections of the knee or hip prosthesis regained full mobility and showed no relapse several months after therapy. In cases of methicillin-resistant Staphylococcus aureus, post-treatment cultures were negative and symptoms had disappeared.
The combination of phage therapy with conservative surgery (the so-called “PhagoDAIR” approach) achieved complete cure in the majority of cases, with no notable adverse effects.

Chronic pulmonary infections, particularly in cystic fibrosis, have shown promising results: in phase 1/2 trials with the AP-PA02 cocktail, treated patients had a reduced bacterial load and improved respiratory function, with a tolerability profile comparable to placebo.

In diabetic foot ulcers, the experimental treatment TP-102 led to wound closure in nearly 75% of treated cases, compared with about 34% under placebo. Phages targeting Pseudomonas, Staphylococcus aureus, and Acinetobacter baumannii thus demonstrated effectiveness, with perfect tolerability.

Pour les infections urinaires causées par E. coli, plusieurs essais (crPhage LBP-EC01, SNIPR001) ont confirmé la bonne tolérance et la réduction initiale de la charge bactérienne, sans effets secondaires graves.

Finally, exceptional cases—such as disseminated Mycobacterium abscessus infections treated with genetically engineered phages—have led to complete clinical and functional recoveries, highlighting the flexibility and power of this approach.

Overall, whether dealing with infected wounds, osteomyelitis, or severe respiratory infections, phage therapy has enabled lasting remissions in situations where antibiotics had failed.

Georgia: a favorable setting for phage therapy

On SeSoignerEnGeorgie.com, we publish articles dedicated to alternative treatments in Georgia, including phage therapy.
Georgia stands out for:

authorized clinical centers providing phage therapy under medical supervision,
GMP-certified laboratories producing high-quality phage preparations
and regulations that are favorable to therapeutic innovation.

To learn more:

Georgia tus offers international patients a safe and innovative medical environment, combining scientific expertise with personalized support.